---
title: "Policy Pulse - Global Spillover - 30 Sep 2026"
ticker: "QQQ:SPY:NVDA:AVGO:AMD:MU:TCS:INFY:WIPRO:HCLTECH:TECHM:TLT:JPM:MS:BAC:GLD:XOM:CVX:OXY:COP:EOG:SLB:BKR:FICO:KMX:GO:DAL:UAL:AAL:LUV:CCL:RCL:NCLH:USO:VLO:PSX:MPC:HINDPETRO:BPCL:IOC:WMT:TGT:COST:HD:LOW:AMZN:MAT:HAS:BTU:ARCH:CEIX:GM:F:LEA:BA:CAT:DE:AGCO:MP:USAR:AREC:FEAM:TM:HMC:MUFG:SMFG:MFG:SUNPHARMA:DRREDDY:CIPLA:DIVISLAB:TORNTPHARM:ALKEM:BIOCON:LUPIN:AUROPHARMA:ZYDUSLIFE:GLENMARK:IPCALAB:PPLPHARMA:LLY:MRK:JNJ:PFE:ABBV:TEVA:VTRS:GSK:NVS:AZN:SNY:NUE:STLD:CLF:X:JINDALSTEL:SAIL"
date: "2026-09-30"
tags: ["policy-pulse","global","fed","boj","oil","pharma"]
summary: "The G20 Trade Ministerial opened in Milwaukee on steel excess capacity, MFN erosion and forced labour - the same ground as the Section 301 tariffs under challenge at the Court of International Trade - while core PCE at 3.0% cut October Fed hike odds from 71% to 35% and eased the front end. Saudi Arabia restarted the East-West pipeline and Yanbu loadings, Gulf exports recovered to 23.3 mbpd with Brent near $103, and India kept 0% Section 232 tariffs on specialty drugs, supporting SUNPHARMA and DRREDDY."
model: "deepseek-v4-flash"
---

## Milwaukee: Steel Overcapacity, the MFN Principle and Forced Labour

**The G20 Trade Ministers' Meeting opened in Milwaukee, Wisconsin on September 30 and runs to October 1**, hosted by **USTR Jamieson Greer**. The agenda is unusually specific for a G20 ministerial, and four of its items are live investment themes:

- **Eliminating forced labour in global supply chains** — the same stated basis for the Section 301 tariffs now under challenge at the US Court of International Trade in Manhattan on the same morning
- **"Updating" the Most-Favoured-Nation principle** — the most consequential item on the list, because MFN erosion is precisely what the past two years of tariff architecture have engineered
- **Denouncing the weaponisation of trade in food**
- **Addressing structural excess capacity and production** — preceded on the morning of September 30 by a **Global Forum on Steel Excess Capacity Ministerial**
- Greer also took the ministers on a tour of **Rockwell Automation**, framed around US reindustrialisation, with the closing reception at the Harley-Davidson Museum

**The steel session is the one to read against the week's domestic news.** Three days before the ministerial, the President announced a **$15 billion Mesabi Metallics mill in Iowa** — 7.5 million short tons of first-year capacity ramping toward 10 million, 1,750 permanent jobs, production targeted for 2030 — and explicitly **credited the 50% steel tariffs** for it. A forum on structural excess capacity is where Washington tells the rest of the world that steel capacity is a national-security problem, while crediting tariffs for adding domestic capacity.

Also in Milwaukee: **Commerce and Industry Minister Piyush Goyal is in the United States from September 29 to October 5**, with a bilateral against Greer on the India-US Bilateral Trade Agreement, and the **Prime Minister and the President spoke by telephone on September 30** (see the India edition).

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| NUE / STLD / CLF / X | 🟢 Positive (policy) / 🔴 Negative (litigation) | Tariff-protected domestic steel is the policy winner of the week, while the same tariff architecture faces a court challenge the same morning | Medium-High |
| TATASTEEL / JSWSTEEL / SAIL / JINDALSTEL (India) | 🟡 Watch | Steel is where India is most exposed to both the Section 232 wall and pending excess-capacity investigations; a G20 framing of "structural excess capacity" is a systemic risk to Indian steel exports, not a benefit | Medium |
| WMT / TGT / COST / AMZN | 🟡 Watch | The forced-labour workstream is the justification for the tariffs these importers pay; a strike-down would cut landed costs, a tightening would raise them | Medium |
| CAT / DE / AGCO | 🟡 Watch | "Weaponisation of trade in food" and agricultural market access are the agri-equipment read-through, with the US-China Board of Trade agri working group as the live mechanism | Medium |
| BA | 🟢 Positive | Aircraft and aircraft parts are named in the India-US $500bn purchase basket that the Milwaukee bilateral is meant to advance | Low-Medium |

---

## The PCE Print and the Global Rate Trade

**The August core PCE print of 3.0% — against 3.3% expected — cut the priced probability of a Fed hike at the late-October meeting from roughly 70.9% a week earlier to 34.9%**, sending short-dated Treasury yields lower and equities higher (the full detail is in the US edition). For non-US assets the transmission is threefold:

1. **A softer US front end relieves pressure on emerging-market currencies and local-currency bond markets.** Through September the rupee's problem was not only a $117 crude basket but the widening rate differential that made dollar assets the easier allocation — a lower US front end narrows that gap from the US side
2. **It partially offsets the Fed–BoJ double tightening that drove the yen carry unwind.** The unwind is a spread trade, and one half of the spread just moved the other way; BCA's ¥35 trillion of hedge-fund yen forwards and TS Lombard's ~$1.1 trillion carry estimate are the positions that benefit
3. **It does not fix the long end.** The 30-year was above **5.6% (a June 2002 high)** and the 10-year above **5.25%** at the prior close, with **VIX around 16**. Duration-sensitive trades — TLT, REITs, utilities — get relief from a softer front end while remaining hostage to a term-premium problem generated by $40 trillion of US debt and a heavy auction calendar

Two more global regulatory prints landed on September 30:

- **The UK regulator abandoned mandatory climate disclosures for listed companies** — a direct counterpoint to SEBI's BRSR Core value-chain assurance mandate for India's top 250 listed companies, and a reminder that the compliance-cost trade runs in both directions
- **China extended two trade-barrier probes into the United States until December 27**, keeping a retaliatory lever in place even as the "30-for-30" product lists cut tariffs on $60 billion

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| QQQ / SPY | 🟢 Positive | A 36-point repricing of the October hike odds is a multiple input for global growth equities, and it lands at the end of a second consecutive positive quarter for both indices | Medium-High |
| TLT | 🟡 Watch | Front-end relief is real; the 30-year above 5.6% is the unresolved half of the trade | Medium |
| MUFG / SMFG / MFG | 🟡 Watch | Japanese megabank ADRs benefit from the BoJ's 1.25% policy rate, but a softer US front end narrows the very spread that makes yen funding attractive — the carry trade's unwind becomes less forced, not more | Medium |
| GLD | 🟡 Watch | Softer inflation supports the metals complex at the margin while removing some of the fiscal-risk urgency behind the $4,210 print | Low-Medium |
| TCS / INFY / HCLTECH / WIPRO (India) | 🟢 Positive | Cheaper US front-end funding and a firmer rupee path are the two macro inputs that most affect foreign flows into Indian large caps; the reverse-AI rotation still has not fired on its own merits ⚠️ inferred | Low-Medium |

---

## Two Central Banks, One Week: The BoJ at a 31-Year High and the Fed's First Hike Since 2023

The defining global event of the past fortnight is that **the world's two largest central banks tightened in the same week**, and both did so against energy-driven inflation rather than domestic overheating.

**Bank of Japan, September 18, 2026 — raised the policy rate to 1.25% from 1.00% by a 7–2 vote.** This is the **highest Japanese policy rate in 31 years** and, per Bloomberg, the **fastest pace of rate hikes in more than three decades**. Dissents came from **Toichiro Asada and Ayano Sato**, both newly appointed by dovish Prime Minister Sanae Takaichi. The statement cited a "moderately recovering economy," a tight labour market, elevated wholesale inflation and business-to-business price pressures that "have started to spill over into consumer prices." It was the **first hike in three months**. Reuters' poll of analysts expects **1.5% by end-March 2027 and 1.75% in Q2 2027, with most seeing the terminal rate at 1.75% or higher**.

**Federal Reserve, September 16, 2026 — raised the target range 25bp to 3.75%–4.00% by a unanimous 12–0 vote.** It is the **first US increase since July 2023**, only nine months after the last cut — the fastest turn from easing to tightening since the early 1990s — and the **first rate change under Chair Kevin Warsh**. The statement's operative language: *"Today's policy action will support a timelier return to the Committee's 2% goal. The Committee will deliver price stability."* Warsh said inflation has been "too high… for too long," that recent data showed a strong economy and labour market, and that **Middle East tension contributed to the decision**. The dot plot showed **16 of 18 participants expecting another increase, four of those seeing two more**, with the policy rate reaching **4.00%–4.25% by end-2026** and holding through 2027. Market odds on a hike at the late-October meeting moved **to 56.5% from 54%**.

**Why this is the number to watch.** BCA Research put outstanding yen forwards held by global hedge funds and principal trading firms at **¥35 trillion (~$226 billion)**, and TS Lombard estimated **total carry-trade exposure at roughly $1.1 trillion** when including all foreign securities bought by Japanese buyers with yen-funded leverage. A Fed at 4% and a BoJ at 1.25% compresses the spread that funded those positions from both ends simultaneously. This is the mechanism that hit Indian equities hardest in the week of September 29, when foreign investors sold roughly ₹10,000 crore of Indian equities in a single session — a fourth consecutive day of selling.

*The table below mixes US-listed and Indian-listed names. Rows containing Indian securities are flagged in the reason column and are covered in full in the India editions of this tracker.*

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| QQQ / SPY | 🔴 Negative | Two of the world's three major central banks tightening in one week compresses the growth-equity multiple from both ends while the 30-year sits above 5.6% | High |
| NVDA / AVGO / AMD / MU | 🔴 Negative | Leveraged AI-chip positions are the most commonly cited yen-carry funding target; a 1.25% BoJ rate is a direct margin-cost increase for those books | Medium-High |
| TCS / INFY / WIPRO / HCLTECH / TECHM | 🟡 Watch | Indian IT is the classic "reverse-AI trade" destination when semis de-rate, but it did **not** fire in the September 29 session — Wipro −2.95%, HCL Tech −2.44% and Tech Mahindra −2.06% were among the worst Nifty 50 performers. The rotation is a thesis, not a current fact | Medium |
| MUFG / SMFG / MFG | 🟢 Positive | The NYSE-listed ADRs of Japan's megabanks are the direct beneficiary of a 1.25% policy rate; the domestic shares rose on the September 30 session (Mitsubishi UFJ +1.20%, Mizuho +2.58%) | High |
| TM / HMC | 🟡 Watch | A stronger yen compresses the translated earnings of Japanese exporters; Toyota moved only +0.56% on the BoJ follow-through, so the FX hit is being offset by domestic demand | Medium |
| TLT | 🔴 Negative | A hawkish Fed plus a hawkish BoJ plus $40 trillion of US debt is the worst combination for long-duration Treasuries | High |

---

## The Long Bond: 30-Year Above 5.6%, a June 2002 High

**The 30-year Treasury yield climbed above 5.6% intraday on September 29 — the highest since June 2002 — and the benchmark 10-year topped 5.29% at its session high, its highest in 24 years.** On September 25 the 10-year reached 5.196%, its highest since 2007, and the 30-year hit 5.513%, a 22-year high. Yields have risen about a full percentage point from the February low.

**Critically, the market did most of the tightening before the Fed moved.** The 10-year touched 5.04% on September 15 — before the September 16 decision — and the 30-year fixed mortgage went from 5.99% at the end of February to **7.22% by mid-September and 7.28% on the eve of the meeting**, all before a single basis point of policy change. The Fed's hike ratified conditions borrowers had already been living with for months.

**The policy response has not worked.** **Treasury Secretary Scott Bessent announced off-schedule purchases of longer-dated bonds** — doubling the original scheduled buyback to $4 billion of 10-to-30-year paper — after US debt crossed **$40 trillion** and the 30-year hit a 19-year high of 5.31%. By September 29 the 30-year was through 5.6% regardless. This is a term-premium repricing, not just a policy-rate repricing: the market is charging more for duration risk at the same time as it prices more hikes.

The equity market's response on September 29 was a quiet grind rather than a break: **Dow 51,349.92 (−0.26%), S&P 500 7,670.84 (−0.17%), Nasdaq 26,797.54 (−0.09%), Russell 2000 2,807.92 (−0.4%)** — all three benchmarks closing off their lows, on back-to-back losing sessions. **Banks led the decline** (JPMorgan, Morgan Stanley, Bank of America; XLF lower), which is the correct tell for a rates story. **Gold rose 0.74% to $4,210.50** — the fiscal-risk read, not the real-rate read.

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| TLT | 🔴 Negative | Above 5.6% on the 30-year is a 24-year high and the Fed has signalled more; duration is where the loss is concentrated | High |
| JPM / MS / BAC | 🔴 Negative | Banks led the September 29 decline and face a higher forward funding curve against a flat long-asset yield | Medium-High |
| LAMR / AMT / PLD / O / SPG / VNQ | 🔴 Negative | Rate-sensitive REITs and outdoor advertising take a 5.6% 30-year straight through the discount rate; Lamar Advertising −5.04% on the session | High |
| GLD | 🟢 Positive | Gold at $4,210 with the long end at multi-decade highs and US debt above $40 trillion is the debasement trade, not a rate trade | Medium-High |
| XOM / CVX / OXY / COP / EOG / SLB | 🟢 Positive | Energy is the natural inflation hedge and oil is up roughly 14% on the month, its biggest monthly climb since July | Medium-High |
| NVDA | 🟢 Positive | A historic buyback announced after the prior close is an explicit valuation defence against multiple compression | Medium |
| FICO | 🔴 Negative | −21.63% on the session after the FHFA moved to introduce competition into mortgage credit scoring — a regulatory re-pricing of a near-monopoly, and a reminder that at 5.6% mortgages the political incentive to cut closing costs is rising | High |
| KMX / GO | 🟢 Positive | Both beat-and-raised through a consumer confidence print at a 2014 low | Medium |

---

## Oil: Brent Settles Around $103 After a 14% Month, and Trump Rules Out Sanctions Relief

**Brent crude fell about 2.1-2.6% to settle around $103.06-$103.20 on September 29**, with **WTI down roughly 3.5% to $89.29-$90.87**. The pullback came on signs of better regional flows — Kpler data showed crude exports from major Middle Eastern producers rising to **12.8 million barrels a day in September, the highest since February**, driven by Saudi Arabia and the UAE. On **September 30 Brent rose again, up 1.11% to $103.73**, after **President Trump denied he was willing to ease sanctions on Iran** while Qatar pushed for peace talks.

**The month is the story, not the day: Brent is on course for a gain of about 14% in September, its biggest monthly climb since July, and WTI after breaching $106 for the first time since May.** The structural drivers are unchanged and physical:

- **Saudi Arabia's East-West crude pipeline went out of service on September 11** and remains off for several weeks, leaving **Hormuz as the only route** for a large share of Gulf exports
- **The Brent-WTI spread has widened to around $13.40 on November contracts**, the widest since May — a symptom of a physically congested Atlantic basin rather than a financial trade
- **Trump rejected an Iranian proposal to reopen the Strait within a week** in exchange for lifting the port blockade, releasing frozen assets and waiving oil sanctions; Iranian officials say talks are off until conditions are met
- US officials say regional flows are normalising, but vessel traffic remains depressed and the security risk is unresolved — the same contradiction Al Jazeera flagged on September 14

**September 30 update — the supply side moved, and against the crude trade.** **Saudi Arabia resumed tanker loadings from its Red Sea port of Yanbu after restarting the East-West pipeline**, which had been out of service since September 11. **Goldman Sachs estimates Gulf oil exports have recovered to 23.3 million barrels a day over the past week**, in line with their 2025 average, as exports doubled through September. Brent traded at **$103.30 (+0.66%)** and WTI at **$90.17 (+0.88%)** in the September 30 session, with Trump again denying reports that he had offered Iran sanctions relief and Qatar running shuttle diplomacy between Tehran and Washington. Downstream, the **White House has urged the EU to draw down emergency diesel inventories** to lower global prices — an admission that the tight part of the barrel is product, not crude. **For the trades in this article that asymmetry is the point: upstream integrateds lose their cleanest catalyst as Gulf flows normalise, while airlines and cruise lines do not get fuel relief until diesel cracks compress.**

**Downstream, this is now rationing.** In India, **Reliance Industries and Nayara Energy began limiting diesel and petrol sales at select outlets**, with Jio-BP capping some sites at 50 litres per customer and 6,000 litres per day, and Nayara limiting transactions to 70–200 litres — while state-owned IOC, BPCL and HPCL continue selling without limits. **India's crude basket averaged $117.4 a barrel on September 21 against roughly $66 across FY26**, and ICRA estimates a **combined daily loss of about ₹530 crore** for the OMCs on negative ₹8/litre petrol and ₹9/litre diesel margins plus LPG under-recoveries of about ₹300 per cylinder. **Russia has banned diesel exports** and may extend; the US has weighed curbs on outbound shipments; and the White House has offered assurances it will not impose a diesel export ban.

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| XOM / CVX / OXY / COP / EOG / SLB / BKR | 🟢 Positive | A 14% monthly Brent gain with the East-West pipeline still offline and sanctions relief explicitly ruled out is close to a best case for upstream integrateds and services | High |
| USO | 🟢 Positive | The commodity itself is the direct expression of the move; note the $13 Brent-WTI spread means the two benchmarks are no longer interchangeable exposures | Medium-High |
| DAL / UAL / AAL / LUV | 🔴 Negative | Jet fuel tracks the distillate complex, and US diesel has been at records with gasoline above $4.20; this is the most direct cost transmission in the S&P | High |
| CCL / RCL / NCLH | 🔴 Negative | Fuel cost plus consumer discretionary exposure, with the Conference Board confidence index at a 2014 low of 81.9 | Medium-High |
| VLO / PSX / MPC | 🟢 Positive | Refining margins widen when the crude spread is this wide and diesel is the scarce product; export economics dominate domestic retail | Medium-High |
| HINDPETRO / BPCL / IOC | 🔴 Negative | Indian state marketers must absorb ₹530 crore a day without raising pump prices — the clearest policy-constrained loser in this oil regime (Indian names; see the India coverage for the full mapping) | High |

---

## US-China "30-for-30" and the G20 Trade Ministerial in Milwaukee

**On September 28 the US and China released reciprocal tariff-cut lists covering roughly $30 billion each.** The US list covers **77 categories of Chinese goods**; China's covers **1,619 categories of US goods**, with over 90% moving to most-favoured-nation rates. The baseline structure is unchanged (30% on Chinese goods, 10% on US goods) and the truce is **extended to January 10, 2027**. Full detail is in the US coverage; the global read is that the two countries that spent 2025 escalating are now scheduling product-list reviews rather than tariff hikes, and a Board of Trade with an agricultural market-access working group has been institutionalised.

**The trade calendar's next test is today and tomorrow.** **The G20 Trade Ministers' Meeting runs September 30 and October 1 in Milwaukee, Wisconsin**, at the invitation of the USTR. **Commerce and Industry Minister Piyush Goyal is in the United States from September 29 to October 5** and will hold bilateral talks with **US Trade Representative Jamieson Greer** on the India-US Bilateral Trade Agreement. India's commerce ministry frames it as "ongoing efforts to advance a balanced and mutually beneficial India-US BTA and finalise an interim deal in line with the Joint Statement of 7 February 2026."

The February framework's headline commitment: **India to purchase $500 billion of American energy products, aircraft and aircraft parts, precious metals, technology products and coking coal over five years.** Goyal has said the pact is "almost done and dusted" and will be executed once Washington gives India the right competitive advantage. **The last-mile issue is preferential access over Vietnam, Bangladesh and Thailand** — India wants a tariff *edge*, not just a lower headline rate. Goyal will also meet chief executives of US manufacturers, consumer-goods, agri-business, retail and technology companies in Milwaukee and Chicago.

**What is still unresolved against India:** US legislation authorising higher tariffs on major purchasers of Russian oil, and pending **Section 301 investigations into structural excess capacity**. India's Congress party has criticised the government's handling after the US House passed a bill empowering the President to impose tariffs on countries buying Russian oil and gas.

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| WMT / TGT / COST / HD / LOW / AMZN | 🟢 Positive | Toys, ornaments, fireworks, tableware and small appliances are on the US cut list, and the truce extension to January 10 removes a Q4 cliff | Medium-High |
| BTU / ARCH / CEIX | 🟢 Positive | US coal is explicitly named on China's 1,619-item list | Medium-High |
| MAT / HAS | 🟢 Positive | Toys are the clearest US-side beneficiary category | Medium-High |
| GM / F / LEA | 🟢 Positive | Car seats appear on the US list; a small but direct auto input | Low-Medium |
| BA | 🟢 Positive | Aircraft and aircraft parts are named in the India-US February framework's $500 billion basket, which the Milwaukee bilateral is meant to advance | Medium |
| CAT / DE / AGCO | 🟢 Positive | US agricultural and equipment access improves through China's list and the Board of Trade's agri working group | Medium |
| MP / USAR / AREC / FEAM | 🟢 Positive | Rare earths and critical minerals are named in the US-China outcome as continuing workstreams — the magnet reshoring theme remains live on both the Trump and Beijing tracks | Medium |
| TCS / INFY / HCLTECH | 🟡 Watch | A US-India interim deal is a modest positive for cross-border services sentiment but the BTA is a goods agreement; the visa and H-1B question is not on this agenda | Low |

---

## India-Specific Spillover: Section 232 Pharma Relief for Specialty Drugs

**The United States has included India among 20 jurisdictions eligible for a zero per cent tariff on specified specialty pharmaceutical products and associated ingredients**, per a US Department of Commerce Bureau of Industry and Security notice published in the Federal Register on **September 23, 2026**, with effect for goods entered for consumption from **12:01 a.m. US Eastern on September 29, 2026**.

This lands at the moment the **100% Section 232 tariff on specified patented pharmaceutical products and their associated ingredients takes effect for most covered companies** — it had applied from **July 31** for companies in the first annex, and from **September 29** for the rest.

**What is covered at 0%:**

- **Orphan drugs** (products designated for one or more rare diseases where all approved indications are for such diseases)
- **Nuclear medicines**, **plasma-derived therapies**, **fertility treatments**
- **Cell therapies and gene therapies**, **antibody-drug conjugates (ADCs)**
- **Medical countermeasures** connected to chemical, biological, radiological and nuclear threats
- **Certain animal-health products**, plus **associated ingredients** of all the above

**The other 19 jurisdictions:** Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam. The notice's stated basis is that qualifying products from these jurisdictions can receive 0% because they have a **current or forthcoming trade and security framework agreement with the United States**.

**The two caveats that decide how much this is worth.**

First, **generics were never in scope.** The Section 232 pharmaceutical tariffs apply to specified patent-protected products; generic medicines and their ingredients are **explicitly outside** the measure, and the September 29 notice further clarifies that the definition of "pharmaceutical articles" covers only finished pharmaceutical products, their active pharmaceutical ingredients and the key starting materials of those ingredients. It also adds a zero-tariff provision for products imported **solely for clinical trials, research and development or other non-commercial purposes**.

Second, **most of India's US pharmaceutical exports are generics.** So the exemption's practical value is narrower than the headline suggests: it protects the cost competitiveness of Indian companies supplying the specified specialty categories, and it should not be read as a blanket exemption or as a rescue of the generic book. Reading the September 29 Indian tape, **Dr Reddy's was the top Nifty 50 gainer at +2.53% and Sun Pharma added 1.47%** — consistent with relief, but the two names were already leading on the day.

| Stock | Impact | Reason | Confidence |
|-------|--------|--------|-----------|
| SUNPHARMA | 🟢 Positive | Largest Indian pharma exporter to the US with an established specialty and complex-generics franchise covering the orphan-drug, fertility and biologic categories named in the notice | Medium-High |
| DRREDDY | 🟢 Positive | Top Nifty 50 gainer on September 29 at +2.53%; the specialty portfolio and the US generics base both sit comfortably outside the 100% tariff line | Medium-High |
| CIPLA | 🟢 Positive | Heavily US-exposed with a growing specialty and respiratory franchise; generics exemption removes the tail risk | Medium |
| DIVISLAB / TORNTPHARM / ALKEM | 🟢 Positive | API and complex-manufacturing exposure benefits twice — as a supplier of ingredients to exempt categories and from the generic exclusion | Medium |
| BIOCON / LUPIN / AUROPHARMA / ZYDUSLIFE / GLENMARK / IPCALAB / PPLPHARMA | 🟢 Positive | All are US-facing with complex-generics or specialty pipelines in or adjacent to the exempt categories; the generics carve-out is the larger structural relief | Medium |
| GSK / NVS / AZN / SNY | 🟢 Positive | The NYSE-listed ADRs of the European, UK and Swiss manufacturers that are the other named jurisdictions — the exemption is a Western-alliance list, and those makers get the same 0% treatment | Medium-High |
| LLY / MRK / JNJ / PFE / ABBV | 🟢 Positive | Branded US pharma retains the tariff wall against out-of-scope competitors, while the 20% onshoring incentive for companies moving production to the US stays in force | Medium-High |
| TEVA / VTRS | 🟡 Watch | Generic manufacturers outside the 20 named jurisdictions do not get the specialty exemption, which creates a narrow competitive asymmetry even though generics remain outside Section 232 | Medium |

---

## Coverage note

The daily Policy Pulse series runs Monday to Friday. This edition resumes after the September 17-29 runs did not publish and therefore covers the fortnight's structural events — the **Fed decision of September 16**, the **BoJ decision of September 18**, the **US-China product lists of September 28** and the **Section 232 pharma step-up of September 29** — rather than a single day, with the September 30 additions folded in: the **G20 Trade Ministerial opening in Milwaukee**, the **core PCE print of 3.0%** and its effect on October hike odds, the **restart of Saudi Arabia's East-West pipeline**, and the **UK regulator's retreat from mandatory climate disclosures**. Where a stock is mapped to a policy without being named in the source, that is stated. Estimates of carry-trade exposure are third-party (BCA Research, TS Lombard) and are cited as such. **The global equity session was still in progress when this edition was written; the index levels cited for September 29 are closes, and September 30 references are intraday.**